6-K

UNITED STATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM 6-K

REPORT OFFOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THESECURITIES EXCHANGE ACT OF 1934

For the month of March 2022

Commission File Number: 001-31995

MEDICUREINC.

(Translation of registrant's name into English)

2-1250 Waverley Street

Winnipeg, MB Canada R3T 6C6

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 8a72____.

EXHIBITLIST

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

MEDICURE ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER AND SUCCESSION PLAN

WINNIPEG, MB, March 23, 2022 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported that Chief Financial Officer David Gurvey (CPA, CMA, B.Sc.) is resigning, effective March 25, 2022.

Albert D. Friesen, PhD, CEO and Chair of the Board of Directors, stated, "On behalf of everyone at Medicure and our Board of Directors, we thank David for his contributions to our Company and we wish him well in his future endeavors."

The Company has initiated a search for a new Chief Financial Officer with the capabilities and qualifications to accelerate Medicure's growth and business strategy. Dr. Neil Owens, Chief Operating Officer of the Company, will assume the role of interim Chief Financial Officer upon Mr. Gurvey's resignation.

**About Medicure Inc.**Medicure is a pharmaceutical company focused on the development and commercialization of innovative and affordable therapeutics for the U.S. market. Medicure's sales force markets to physicians and other healthcare professionals and now with E-Commerce integration, will be offering patients and providers direct online ordering and home delivery. Our vision is to become a leading pharmaceutical company within the U.S, offering a growing portfolio of products that improve patients' lives. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug®, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and most territories, including Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or e-mail info@marleydrug.com. For more information on Medicure please visit https://www.medicure.com/. For additional information about AGGRASTAT®, refer to the full Prescribing Information. For additional information about ZYPITAMAG®, refer to the full Prescribing Information.

To be added to Medicure's e-mail list, please visit:     http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracyof this release.

Forward Looking Information: Statements containedin this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes","may", "plans", "will", "estimates", "continues", "anticipates", "intends","expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadianand U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referredto as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of theCompany made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factorswhich the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknownrisks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events ordevelopments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements,and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others,the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a PRV, expectedfuture growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinicaltrials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependenceupon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in theindustry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptionsabout: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company'srevenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and developmentprojects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availabilityof financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance anddemand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Companyundertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, otherthan as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Companyand its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the USSecurities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2020.

View original content:https://www.prnewswire.com/news-releases/medicure-announces-resignation-of-chief-financial-officer-and-succession-plan-301509407.html

SOURCE Medicure Inc.

View original content: http://www.newswire.ca/en/releases/archive/March2022/23/c8086.html

%CIK: 0001133519

For further information: Dr. Albert D. Friesen, Chief Executive Officer, Tel. 888-435-2220, Fax 204-488-9823, E-mail: info@medicure.com, www.medicure.com

CO: Medicure Inc.

CNW 17:00e 23-MAR-22